目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T3452 | c-Kit | ||
ISCK03 是一种特异性的 SCF/c-Kit 抑制剂。 | |||
T5409 | c-Kit | ||
AZD3229 是一种突变型酪氨酸激酶受体抑制剂,可用于胃肠道间质瘤的研究。 | |||
T4320 | Bcr-Abl PDGFR c-Kit | ||
Flumatinib (HHGV678) 是一种具有口服活性的选择性 Bcr-Abl 抑制剂,能够作用于 c-Abl (IC50:1.2 nM),PDGFRβ (IC50:307.6 nM) 和 c-Kit (IC50:665.5 nM)。 | |||
T9689 | c-Kit | ||
M4205 是一种 c-Kit 抑制剂,对外显子 11、13、17 中的 c-Kit 突变具有高活性。 | |||
T5109 | PDGFR c-Kit | ||
Avapritinib (BLU-285) 是选择性的、高效的、具有口服活性的 KIT 和 PDGFRA 激活环突变激酶抑制剂,能够作用于 KIT D816V (IC50:0.27 nM) 和 PDGFRA D842V (IC50:0.24 nM)。它减弱 ABCB1 和 ABCG2 的传输功能。它与激酶的活性构象结合,并显示抗肿瘤活性。 | |||
T7945 | VEGFR PDGFR c-Kit | ||
SU14813 是一种多靶点受体酪氨酸激酶抑制剂,能够抑制 VEGFR2 (IC50:50 nM),VEGFR1 (IC50:2 nM),PDGFRβ (IC50:4 nM),KIT (IC50:15 nM)。 | |||
T2288 | VEGFR c-Kit | ||
Motesanib (AMG 706) 是有效的、ATP 竞争性的 VEGFR1/2/3 的抑制剂,其IC50值为 2 nM/3 nM/6 nM,与对 Kit 的选择性相似,是 PDGFR 和 Ret 的 10 倍多。 | |||
T6166 | VEGFR PDGFR c-Kit | ||
Telatinib (Bay 57-9352) 是一种口服具有活力的,小分子的 VEGFR2,VEGFR3,PDGFα 和 c-Kit 抑制剂,它们的 IC50 值分别为6,4,15,1 nM。 | |||
T10652 | c-Fms CSF-1R c-Kit | ||
Vimseltinib (DCC-3014) 是 c-FMS(CSF-IR) 和 c-Kit 抑制剂,IC50值分别为 <0.01 μM 和 0.1-1 μM。 | |||
T4332 | c-Met/HGFR c-Kit | ||
c-Kit-IN-1 (DCC-2618) 是c-Kit 和c-Met 抑制剂(IC50<200 nM)。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-04051 | c-Kit Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
C-Kit is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-Kit contains 5 Ig-like C2-type (immunoglobulin-like) domains and 1 protein kinase domain. It belongs to the protein kinase superfamily, tyr protein kinase family, and CSF-1/PDGF receptor subfamily. C-Kit has tyrosine-protein kinase activity. Binding of the ligands leads to the autophosphorylation of KIT and its association with substrates such as phosphatidylinositol 3-kinase. Antibodies to c-Kit are widely used in immunohistochemistry to help distinguish particular types of tumor in histological tissue sections. It is used primarily in the diagnosis of GISTs. In GISTs, c-Kit staining is typically cytoplasmic, with stronger accentuation along the cell membranes. C-Kit antibodies can also be used in the diagnosis of mast cell tumors and in distinguishing seminomas from embryonal carcinomas. Mutations in the c-Kit gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Defects in KIT are a cause of acute myelogenous leukemia (AML). AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Note=Somatic mutations that lead to constitutive activation of KIT are detected in AML patients.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-01935 | c-Kit Protein, Human, Recombinant (His) | Human | HEK293 | ||
C-Kit is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-Kit contains 5 Ig-like C2-type (immunoglobulin-like) domains and 1 protein kinase domain. It belongs to the protein kinase superfamily, tyr protein kinase family, and CSF-1/PDGF receptor subfamily. C-Kit has tyrosine-protein kinase activity. Binding of the ligands leads to the autophosphorylation of KIT and its association with substrates such as phosphatidylinositol 3-kinase. Antibodies to c-Kit are widely used in immunohistochemistry to help distinguish particular types of tumor in histological tissue sections. It is used primarily in the diagnosis of GISTs. In GISTs, c-Kit staining is typically cytoplasmic, with stronger accentuation along the cell membranes. C-Kit antibodies can also be used in the diagnosis of mast cell tumors and in distinguishing seminomas from embryonal carcinomas. Mutations in the c-Kit gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Defects in KIT are a cause of acute myelogenous leukemia (AML). AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Note=Somatic mutations that lead to constitutive activation of KIT are detected in AML patients.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPK-01270 | CD117 Protein, Cynomolgus/Rhesus macaque, Recombinant (His) | Cynomolgus,Rhesus macaque | HEK293 | ||
The c-kit proto-oncogen (CD117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells. Among normal BM cells, CD117 expression has been found in about half of the CD34 precursors including progenitors committed to the erythroid, granulo-monocytic, and megakaryocytic cell lineages.
|
|||||
TMPK-00777 | CD117 Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
The c-kit proto-oncogen (CD 117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells. Among normal BM cells, CD117 expression has been found in about half of the CD34 precursors including progenitors committed to the erythroid, granulo-monocytic, and megakaryocytic cell lineages.
|
|||||
TMPK-00805 | CD117 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
The c-kit proto-oncogen (CD 117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells. Among normal BM cells, CD117 expression has been found in about half of the CD34 precursors including progenitors committed to the erythroid, granulo-monocytic, and megakaryocytic cell lineages.
|
|||||
TMPY-03567 | c-Kit Protein, Human, Recombinant (aa 50-190, His) | Human | E. coli | ||
C-Kit is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-Kit contains 5 Ig-like C2-type (immunoglobulin-like) domains and 1 protein kinase domain. It belongs to the protein kinase superfamily, tyr protein kinase family, and CSF-1/PDGF receptor subfamily. C-Kit has tyrosine-protein kinase activity. Binding of the ligands leads to the autophosphorylation of KIT and its association with substrates such as phosphatidylinositol 3-kinase. Antibodies to c-Kit are widely used in immunohistochemistry to help distinguish particular types of tumor in histological tissue sections. It is used primarily in the diagnosis of GISTs. In GISTs, c-Kit staining is typically cytoplasmic, with stronger accentuation along the cell membranes. C-Kit antibodies can also be used in the diagnosis of mast cell tumors and in distinguishing seminomas from embryonal carcinomas. Mutations in the c-Kit gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Defects in KIT are a cause of acute myelogenous leukemia (AML). AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Note=Somatic mutations that lead to constitutive activation of KIT are detected in AML patients.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-06656 | c-Kit Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
C-Kit is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-Kit contains 5 Ig-like C2-type (immunoglobulin-like) domains and 1 protein kinase domain. It belongs to the protein kinase superfamily, tyr protein kinase family, and CSF-1/PDGF receptor subfamily. C-Kit has tyrosine-protein kinase activity. Binding of the ligands leads to the autophosphorylation of KIT and its association with substrates such as phosphatidylinositol 3-kinase. Antibodies to c-Kit are widely used in immunohistochemistry to help distinguish particular types of tumor in histological tissue sections. It is used primarily in the diagnosis of GISTs. In GISTs, c-Kit staining is typically cytoplasmic, with stronger accentuation along the cell membranes. C-Kit antibodies can also be used in the diagnosis of mast cell tumors and in distinguishing seminomas from embryonal carcinomas. Mutations in the c-Kit gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Defects in KIT are a cause of acute myelogenous leukemia (AML). AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Note=Somatic mutations that lead to constitutive activation of KIT are detected in AML patients.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-04564 | c-Kit Protein, Human, Recombinant (aa 540-972, His & GST) | Human | Baculovirus-Insect Cells | ||
C-Kit is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-Kit contains 5 Ig-like C2-type (immunoglobulin-like) domains and 1 protein kinase domain. It belongs to the protein kinase superfamily, tyr protein kinase family, and CSF-1/PDGF receptor subfamily. C-Kit has tyrosine-protein kinase activity. Binding of the ligands leads to the autophosphorylation of KIT and its association with substrates such as phosphatidylinositol 3-kinase. Antibodies to c-Kit are widely used in immunohistochemistry to help distinguish particular types of tumor in histological tissue sections. It is used primarily in the diagnosis of GISTs. In GISTs, c-Kit staining is typically cytoplasmic, with stronger accentuation along the cell membranes. C-Kit antibodies can also be used in the diagnosis of mast cell tumors and in distinguishing seminomas from embryonal carcinomas. Mutations in the c-Kit gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Defects in KIT are a cause of acute myelogenous leukemia (AML). AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Note=Somatic mutations that lead to constitutive activation of KIT are detected in AML patients.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPJ-00402 | CD117 Protein, Human, Recombinant (hFc) | Human | Human Cells | ||
C-Kit/SCF R is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-Kit contains 5 Ig-like C2-type (immunoglobulin-like) domains and 1 protein kinase domain. It belongs to the protein kinase superfamily and CSF-1/PDGF receptor subfamily. SCF R expression on mast cells enables them to infiltrate SCF-secreting tumors where they promote tumor growth and induce local immune suppression. SCF R is up-regulated on dendritic cells by Th2-orTh17-biasing stimuli, and it is required for subsequent dendritic cell induction of Th2 and Th17 responses. SCF R protects vascular smooth muscle cells from apoptosis and assists in the recovery of cardiac function following myocardial infarction.
|